Alivus Life Sciences Ltd.

₹1066.2

Alivus Life Sciences Ltd.

₹1066.2

₹1066.2

12.6 (1.2%) - 16 Jul 2025 04:25 PM

About Company

Glenmark Life Sciences Limited is a leading developer and manufacturer of select high value, non-commoditized active pharmaceutical ingredients (APIs) in chronic therapeutic areas, including cardiovascular disease (CVS), central nervous system disease (CNS), pain management and diabetes. It also manufacture and sell APIs for gastro-intestinal disorders, anti-infectives and other therapeutic areas. Its API portfolio comprises specialized and profitable products, including niche and technically complex molecules, which reflects its capability to branch into other high value products. It has strong market share in select specialized APIs such as Telmisartan (anti-hypertensive), Atovaquone (anti-parasitic), Perindopril (anti-hypertensive), Teneligliptin (diabetes), Zonisamide (CNS) and Adapalene (dermatology). The company currently operates four multi-purpose manufacturing facilities which are situated on leasehold properties located at Ankleshwar and Dahej in the state of Gujarat, India, and Mohol and Kurkumbh in the state of Maharashtra, India.

Market Cap. ₹ 12,920 Cr.
52 Week - High/Low ₹ 1,335/819
P/E Ratio 26.58
P/B Ratio 5.54
Enterprise Value ₹ 12,973 Cr.
ROE % 21.15
RSI Value 61.13
EMA 50 1035.81
EMA 200 1028.29
Market Cap. ₹ 12,920 Cr.
52 Week - High/Low ₹ 1,335/819
P/E Ratio N/A
P/B Ratio N/A
Enterprise Value -
ROE % N/A
RSI Value 61.13
EMA 50 1035.81
EMA 200 1028.29

Growth

Valuation

Calculators

Peer Comparison

Industry - Pharmaceuticals & Drugs

* Please refer to the Standalone data if Consolidated financial data for the company is not available.

Shareholding Pattern Numbers in percentages

Insight market
Copyright © 2025 All rights reserved with INVESMATE INSIGHTS PRIVATE LIMITED | All logos and Trademarks registered with their respective owners.